...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Folia histochemica et cytobiologica >JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients
【24h】

JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients

机译：原发性血小板增多症（ET）患者的JAK2突变状态，止血危险因素和血栓形成因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The recently discovered JAK2 V617F point mutation, found in 50-60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We examined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothrombotic genes mutations: factor V Leiden, prothrombin and MTHFR. We also evaluated plasma levels of fibrinogen, factors VIII and XII, AT, protein C, protein S and serum level of homocysteine. Urokinase concentration was assessed in patients' plasma as well as platelet lysates. There was no difference in the number of thrombotic complications between ET patients with and without JAK2 mutation. However, we found a number of thrombophilic and hemostatic risk factors that could contribute to thrombotic complications in ET patients.
机译：据报道，在50-60％的ET患者中发现了最近发现的JAK2 V617F点突变，与血栓形成事件的风险较高有关。在这项研究中，我们探讨了JAK2 V617F突变或并存的血栓形成和止血危险因素是否导致了这些并发症。我们检查了32例ET患者，并寻找了致病性JAK2 V617F突变和血栓前基因突变：因子V Leiden，凝血酶原和MTHFR。我们还评估了血浆纤维蛋白原，因子VIII和XII，AT，蛋白C，蛋白S和高半胱氨酸的血清水平。评估患者血浆以及血小板裂解物中的尿激酶浓度。有和没有JAK2突变的ET患者之间的血栓并发症数量没有差异。然而，我们发现了许多可能导致ET患者血栓并发症的血栓形成和止血危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号